الرئيسية › سرطان الثدي الثلاثي السلبي › نيويورك › New York City
التجارب السريرية لـ سرطان الثدي الثلاثي السلبي في New York City، NY
31 دراسات لـ سرطان الثدي الثلاثي السلبي تبحث عن مشاركين في مواقع داخل وحول New York City (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- و 2 أخرى
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
جارٍ التسجيلالمرحلة 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
جارٍ التسجيلالمرحلة 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Avenzo Therapeutics Recruiting Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
جارٍ التسجيلدراسة رصدية
- NYU Langone Medical Center, New York
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
جارٍ التسجيلالمرحلة 3
- Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
جارٍ التسجيلالمرحلة 3
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York
- Icahn School of Medicine at Mount Sinai ( Site 0123), New York
- Memorial Sloan Kettering Cancer Center ( Site 0067), New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
جارٍ التسجيلالمرحلة 1
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
جارٍ التسجيلالمرحلة 1
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Mount Sinai, New York
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
جارٍ التسجيلالمرحلة 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
جارٍ التسجيلالمرحلة 2
- NYP/Weill Cornell Medical Center, New York
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
جارٍ التسجيلالمرحلة 3
- Laura and Isaac Perlmutter Cancer Canter, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
جارٍ التسجيلالمرحلة 2
- Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
جارٍ التسجيلالمرحلة 2/3
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street., New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
جارٍ التسجيلالمرحلة 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
جارٍ التسجيلالمرحلة 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
جارٍ التسجيلالمرحلة 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
جارٍ التسجيلالمرحلة الأولى المبكرة
- Mount Sinai Health System, New York
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
جارٍ التسجيلالمرحلة 2
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York
- Columbia University Medical Center, New York
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
جارٍ التسجيلالمرحلة 1/2
- NYU Langone perimutter Cancer Center, New York
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
جارٍ التسجيلالمرحلة 1
- Memorial Sloan Kettering Cancer Center, New York
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
جارٍ التسجيلالمرحلة 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
جارٍ التسجيلالمرحلة 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
جارٍ التسجيلالمرحلة 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
جارٍ التسجيلالمرحلة 1/2
- NYU Langone Health, New York
تجارب سرطان الثدي الثلاثي السلبي في مدن أخرى
- Houston, TX42 دراسات
- Nashville, TN28 دراسات
- Los Angeles, CA27 دراسات
- Boston, MA26 دراسات
- San Antonio, TX23 دراسات
- St. Louis, MO21 دراسات
- Arlington, VA20 دراسات
- Atlanta, GA20 دراسات
- Dallas, TX18 دراسات
- Chicago, IL16 دراسات
- Columbus, OH16 دراسات
- Grand Rapids, MI15 دراسات
دراسات أخرى في New York City
- سرطان الثدي136 دراسات
- سرطان الرئة غير صغير الخلايا121 دراسات
- السرطان (جميع الأنواع)109 دراسات
- سرطان البروستاتا103 دراسات
- السرطان النقيلي93 دراسات
- سرطان القولون والمستقيم78 دراسات
- سرطان المبيض69 دراسات
- سرطان الرئة60 دراسات
- الورم النقوي المتعدد60 دراسات
- سرطان البنكرياس60 دراسات
- سرطان بطانة الرحم52 دراسات
- ابيضاض الدم النقوي الحاد51 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.